Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer
Nicholas C. Turner(Royal Marsden NHS Foundation Trust), Susan Cleator(Institute of Cancer Research)
Cited by 184
Related Papers
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
|Annals of Oncology|2022|633
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
|Clinical Cancer Research|2010|323
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
|Nature Communications|2020|258
Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
|Clinical Cancer Research|2019|136